Effectiveness of these therapies will depend on their ability to target potent tumor-specific or tumor-associated antigens, overcome the mechanisms of immune tolerance, and nullify immunosuppressive pathways (e.g. PD-1/L1, CTLA-4, etc.)[103]. The gene discussed is CTLA4; the disease is neoplasm.